Theralase's Light-Activated Bladder Cancer Therapy Shows Promising Results in Phase II Trial
Key Insights
Theralase's innovative light-activated therapy Ruvidar™ demonstrates sustained efficacy with responses lasting over 3 years in BCG-unresponsive bladder cancer (search) patients.
The Phase II clinical trial data has been selected for podium presentation at the 2025 American Urological Association (search) Annual Meeting, highlighting its potential impact on bladder cancer (search) treatment.
The company plans to complete patient enrollment in 2025, submit data to regulators in 2026, and aims for commercial availability by 2027, pending approval.
Theralase Technologies (search) has announced promising interim results from its Phase II clinical trial of Ruvidar™, a novel light-activated therapy for bladder cancer (search) patients who have failed standard BCG treatment. The data will be presented at the upcoming American Urological Association (search) (AUA) Annual Meeting in Las Vegas, scheduled for April 26-29, 2025.
The multicenter study evaluates Ruvidar™ (TLD-1433) in patients with BCG-unresponsive non-muscle invasive bladder cancer (search) (NMIBC) carcinoma in-situ (CIS). Early results show remarkable durability, with several patients maintaining response for three years or longer after a single treatment session.
Clinical Trial Details and Patient Impact
The ongoing Phase II trial is recruiting 75-100 patients across 15 clinical sites in Canada and the United States. The treatment utilizes a therapeutic dose of 0.70 mg/cm² of Ruvidar™, activated by the proprietary TLC-3200 Medical Laser System.
"The early data is supportive of light-activated Ruvidar™ as a treatment modality for BCG-unresponsive CIS of the bladder, enabling patients to preserve their bladders and maintain their quality of life," said Dr. Girish Kulkarni, principal investigator and urologic surgeon at the Princess Margaret Cancer Centre.
Innovative Technology and Mechanism
Ruvidar™ represents a significant advancement in targeted cancer therapy. The small molecule compound is designed to selectively destroy cancer cells (search) while minimizing damage to surrounding healthy tissue. This approach offers hope to patients who have exhausted standard treatment options and face the prospect of radical cystectomy (bladder removal).
Dr. Arkady Mandel, Chief Scientific Officer at Theralase, emphasized the treatment's efficiency: "The latest results demonstrate a long-lasting duration of complete response induced by this innovative technology, which can be completed within a few hours."
Development Timeline and Future Applications
Theralase has outlined an ambitious development timeline for Ruvidar™:
- Patient enrollment completion: 2025
- Regulatory submission to Health Canada and FDA: 2026
- Targeted commercial launch: 2027
Beyond bladder cancer (search), the company plans to evaluate Ruvidar™'s potential in treating other cancers, including brain, lung, pancreatic, and muscle-invasive bladder cancer.
Safety and Efficacy Profile
The interim data demonstrates both strong safety and efficacy profiles across multiple clinical study sites. This is particularly significant for high-grade, high-risk NMIBC patients who have limited treatment options after BCG failure.
Roger DuMoulin-White, CEO of Theralase, noted that the selection for podium presentation at the AUA Annual Meeting "is a testament to the importance and significant impact this clinical research could have on the lives of bladder cancer (search) patients."